logo
Share SHARE
FONT-SIZE Plus   Neg

Merck, GE Healthcare Collaborate For BACE Inhibitor Development Program

Merck (MRK), known as MSD outside the U.S. and Canada, and GE Healthcare, an unit of General Electric Co. (GE), announced a study collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational positron emission tomography or PET imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme or BACE inhibitor and Merck's lead investigational candidate for Alzheimer's disease.

According to the agreement, GE Healthcare would supply [18F]Flutemetamol to help select patients for trials and assess this investigational agent as a companion diagnostic tool. A joint Merck and GE Healthcare Imaging Advisory Committee would oversee the planned imaging studies.

"In clinical trials, [18F]Flutemetamol demonstrated consistent performance in the visual detection of beta amyloid in the brain when compared with histopathology data," according to Jonathan Allis, general manager, PET, GE Healthcare Medical Diagnostics.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
IT services provider Computer Sciences Corp (CSC), on Tuesday reported a profit for the third quarter that also trumped estimates, helped largely by lower operating costs that offset 10 percent drop in revenues. Commenting on the results Mike Lawrie said, "In the third quarter, CSC successfully completed... Entertainment giant Walt Disney Co. (DIS) Tuesday reported an increase in first-quarter profit that also trumped Wall Street expectations, as revenues jumped 14 percent on stupendous performance of Star Wars: The Force Awakens. Burbank, California-based Disney's first-quarter profit rose to $2.88... Media conglomerate Viacom, Inc. on Tuesday reported a 10 percent decline in profit for the first quarter from last year, reflecting lower revenues in the Filmed Entertainment and Media Networks segments. However, adjusted earnings per share for the quarter matched analysts' expectations, while revenues missed their estimates.
comments powered by Disqus
RELATED NEWS
Trade MRK now with 
Follow RTT